G
LABU icon

Gainplan’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Gainplan’s Portfolio LABU Stock Details LABU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,000
Closed -$664K – 72
2024
Q1 		$664K Buy
+5,000
New +$653K 0.32% 29
2023
Q3 		– Sell
-3,750
Closed -$444K – 49
2023
Q2 		$444K Buy
+3,750
New +$467K 0.24% 27
2020
Q3 		– Sell
-750
Closed -$891K – 44
2020
Q2 		$891K Buy
+750
New +$650K 0.58% 14
2019
Q4 		– Sell
-750
Closed -$464K – 59
2019
Q3 		$464K Buy
750
+250
+50% +$208K 0.28% 22
2019
Q2 		$502K Buy
+500
New +$484K 0.3% 19
2019
Q1 		– Sell
-500
Closed -$329K – 30
2018
Q4 		$329K Buy
+500
New +$524K 0.32% 11

Other funds holding LABU

TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Gainplan's LABU Position: Q2 2024 in Review

Gainplan sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q2 2024, closing a stake of 5,000 shares — an estimated $664K sold.

Gainplan first reported a position in LABU in Q4 2018 and held it in 6 quarters. The position peaked at $891K in Q2 2020. 37 funds tracked by Wall St. Rank hold LABU as of Q2 2024.

  • Gainplan reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q2 2024 after selling out during the quarter.
  • Gainplan sold 5,000 Direxion Daily S&P Biotech Bull 3X ETF shares in Q2 2024, an estimated $664K.
  • Gainplan first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q4 2018 and held it in 6 quarters.
  • Gainplan's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $891K in Q2 2020.
  • 37 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q2 2024.

Based on Gainplan's 13F filing for Q2 2024, filed 12 Jul 2024.